Skip to content
value.today

Alembic Pharmaceuticals Limited

APLLTD.BO
$2.2 Bmarket cap on Nov 19, 2026+15.4% since Jan 2024
1D
+0.7%
Compare
World rank
#6,005
Revenue
$664 M
Mar-2022 ending year
value.today research
Net income
$68 M
10.2% margin
value.today research
Employees
11,576
As on March 2020
value.today research

Alembic Pharmaceuticals Limited in brief

Alembic Pharmaceuticals Limited is a listed company in the Pharmaceutical industry, based in Vadodara, India. It was founded in 1907. Its market value was $2.2 B on 19 November 2026, which makes it the 6,005th largest listed company in the world and the 371st largest in India on this site. In the year to Mar 2022 it had sales of $664 M and a net profit of $68 M, about 10 cents of profit for every dollar of sales. It employs about 11,576 people. Its shares trade under the symbol APLLTD.BO (BSE).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals is an Indian multinational pharmaceutical company headquartered in Vadodara, Gujarat. The company manufactures and markets pharmaceutical products, including active pharmaceutical ingredients (APIs) and formulations, and has a presence in the macrolide anti-infective drug segment.

Alembic Pharmaceuticals produces formulations for therapeutic areas such as cardiology, dermatology, diabetes, ophthalmology, and infectious diseases for domestic and international markets. It operates manufacturing facilities in Gujarat (Panelav and Karakhadi), Sikkim, and Pithampur as well as research and development centres in India and the United States.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Alembic Pharmaceuticals Limited timeline

2 events, 1907–2011
  1. 1907
  2. 🏁
    · approximate
    Founded
  3. 2011
  4. 📈
    Listed on National Stock Exchange of India as APLLTD
    First day of listing in the exchange's official list.

Events of Alembic Pharmaceuticals Limited from Wikidata and the exchanges' official lists. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Alembic Pharmaceuticals Limited share price · NSE (APLLTD.NS)

daily · 2,473 trading days since 2016
Last close 1,050 INR (Nov 19, 2026)1 month: +32.8%1 year: +15.8%5 years: +38.1%10 years: +72.0%52-week range 635.80 – 1,075 INR
$0 M$337 M$674 M$1.0 B$1.3 B2017201820192020202120222023202420252026
DateOpenHighLowCloseChangeVolume
Nov 19, 20261,0441,0541,0391,050+0.5%333,407
Nov 18, 20261,0411,0601,0411,044-0.6%228,735
Nov 17, 20261,0581,0621,0451,051-0.6%201,850
Nov 16, 20261,0341,0751,0341,057+2.6%452,099
Nov 13, 20261,0491,0731,0241,030-1.6%422,868
Nov 12, 20261,0371,0551,0301,047+1.7%452,715
Nov 11, 20261,0231,0521,0211,030+1.2%540,258
Nov 9, 20261,0151,0561,0061,017+5.4%980,734
Nov 6, 2026894.80985.00890.00965.15+8.0%2.4 M
Nov 5, 2026919.70936.95885.60893.50-1.5%1.9 M
Nov 4, 2026808.00963.35803.65906.70+12.9%4.2 M
Nov 3, 2026803.00814.85798.50802.80-0.0%92,294
Nov 2, 2026801.10806.70786.50803.00+0.6%97,135
Oct 30, 2026794.85800.00784.05797.85+0.4%72,865
Oct 29, 2026780.40801.00776.00794.85+1.5%63,490
Oct 28, 2026769.95788.00765.90782.80+2.1%125,417
Oct 27, 2026762.55779.00761.80766.90+0.1%203,141
Oct 26, 2026759.45769.55753.55766.40+0.8%43,824
Oct 23, 2026775.00776.00748.25760.10-2.7%120,847
Oct 22, 2026779.00786.95777.15781.30-0.8%45,524
Oct 21, 2026794.20794.70781.30787.95-0.3%61,315
Oct 19, 2026790.05799.00779.00790.35+0.1%137,411
Oct 16, 2026792.65793.00771.00789.45-0.4%148,103
Oct 15, 2026797.95802.40789.25792.65+0.0%77,862
Oct 14, 2026789.05799.15785.80792.45-0.7%70,461
Oct 13, 2026787.10800.00778.85797.85+1.1%70,432
Oct 12, 2026796.95806.00786.20789.05-1.5%110,567
Oct 9, 2026801.00806.20788.75800.95+0.1%187,843
Oct 8, 2026833.80835.10797.95800.50-4.0%171,505
Oct 7, 2026834.10839.00821.25833.80—135,889

Prices in INR from the National Stock Exchange of India; the last 30 trading days are listed, the chart shows up to ten years. For information only; not investment advice.

Alembic Pharmaceuticals Limited share price statistics

computed nightly from the daily prices
NSE · APLLTD.NSClose 1,050 INR (Nov 19, 2026)
1 day
+0.5%
1 week
+0.2%
1 month
+32.8%
3 months
+28.4%
Year to date
+24.0%
1 year
+15.8%
3 years
+42.4%
5 years
+38.1%
10 years
+74.3%
52-week low 635.80-2.4% from the highhigh 1,075
Highest on record 1,304 INR (Oct 9, 2024)Volume 470,198 shares/dayValue traded 437.8 M INR/dayVolatility 48% (30d), 31% (1y)2,474 trading days on record

Changes compare closing prices; volatility is the annualised standard deviation of daily returns. Prices are as published by the exchange, not adjusted for splits, bonus issues or dividends. For information only; not investment advice.

Market cap history

$0 M$756 M$1.5 B$2.3 B$3.0 B2020202120222023202420252026

World rank over time

▲ up 113 places since 2020
2020-01-01: #6119#6,11920202021-01-01: #4477#4,47720212022-01-07: #6046#6,04620222022-12-25: #6905#6,90520222023-07-30: #5995#5,99520232024-01-05: #5840#5,84020242026-03-08: #3496#3,49620262026-11-12: #6100#6,10020262026-11-13: #6167#6,16720262026-11-16: #6012#6,01220262026-11-17: #6019#6,01920262026-11-18: #6036#6,03620262026-11-19: #6006#6,0062026

Rank in India: #228 (Jan 2020) · #172 (Jan 2021) · #285 (Jan 2022) · #314 (Dec 2022) · #294 (Jul 2023) · #340 (Jan 2024) · #358 (Mar 2026) · #373 (Nov 2026) · #376 (Nov 2026) · #370 (Nov 2026) · #371 (Nov 2026) · #372 (Nov 2026) · #371 (Nov 2026)

Key ratios

market cap and latest results
P/E ratio
32.5×
Price / sales
3.3×
Price / book
3.4×
Free cash flow yield
—
Net margin
10.2%
Operating margin
—
Return on equity
10.4%
Liabilities / assets
26.5%
Revenue per employee
$57 K
Profit per employee
$6 K

Annual results

Revenue
$664 M
Operating income
—
Net income
$68 M

Mar-2022 ending year

Balance sheet

Total assets
$891 M
Total liabilities
$236 M
Total equity
$656 M

Mar-2022 ending year

Mutual funds holding Alembic Pharmaceuticals Limited#

45 funds in 2 countries hold shares worth $79 M. Since their previous reports 4 added shares and 11 sold, selling $1 M net. By country: India 7 ($46 M), USA 38 ($33 M).
Mutual funds holding Alembic Pharmaceuticals Limited
FundSharesValueOf the companyOf the fundChange in sharesReport
🇮🇳 DSP Small Cap FundDSP Asset Managers1.50 M$13 M—0.59%no changeOct 31, 2026
🇮🇳 DSP Healthcare FundDSP Asset Managers1.44 M$12 M—3.1%no changeOct 31, 2026
🇮🇳 DSP ELSS Tax Saver FundDSP Asset Managers1.43 M$12 M—0.73%no changeOct 31, 2026
🇺🇸 Vanguard Total International Stock Index FundThe Vanguard Group, Inc.833,878$7 M—<0.01%no changeJul 31, 2026
🇮🇳 DSP Aggressive Hybrid FundDSP Asset Managers799,463$7 M—0.57%no changeOct 31, 2026
🇺🇸 Vanguard Emerging Markets Stock Index FundThe Vanguard Group, Inc.785,700$7 M—<0.01%no changeJul 31, 2026
🇺🇸 iShares Core MSCI Emerging Markets ETFBlackRock Fund Advisors765,673$6 M—<0.01%+0.0%May 31, 2026
🇺🇸 Emerging Markets Core Equity 2 PortfolioDimensional Fund Advisors LP478,490$4 M—0.01%−1.9%Jul 31, 2026
🇺🇸 Vanguard Ftse All-World Ex-Us Small-Cap Index FundThe Vanguard Group, Inc.219,611$2 M—0.01%no changeJul 31, 2026
🇺🇸 The Emerging Markets Small Cap SeriesDimensional Fund Advisors LP186,858$2 M—0.04%no changeJul 31, 2026
🇮🇳 DSP Multi Cap FundDSP Asset Managers127,660$1 M—0.36%no changeOct 31, 2026
🇮🇳 DSP Equity Savings FundDSP Asset Managers99,017$1 M—0.26%no changeOct 31, 2026
🇺🇸 WisdomTree India Earnings FundWisdomTree Asset Management, Inc.91,291$1 M—0.04%−5.6%Jun 30, 2026
🇺🇸 iShares MSCI India Small-Cap ETFBlackRock Fund Advisors87,703$1 M—0.11%−8.3%May 31, 2026
🇺🇸 Dimensional Emerging Markets Value FundDimensional Fund Advisors LP72,031$1 M—<0.01%−11%Jul 31, 2026
🇺🇸 Dimensional Emerging Markets Core Equity 2 ETFDimensional Fund Advisors LP65,097$1 M—<0.01%no changeJul 31, 2026
🇮🇳 DSP Value FundDSP Asset Managers61,327$1 M—0.21%no changeOct 31, 2026
🇺🇸 WisdomTree Emerging Markets SmallCap Dividend FundWisdomTree Asset Management, Inc.54,308$0 M—0.03%−1.1%Jun 30, 2026
🇺🇸 Avantis Emerging Markets Equity ETFAmerican Century ETF Trust58,537$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Total World Stock Index FundThe Vanguard Group, Inc.46,523$0 M—<0.01%no changeJul 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC39,863$0 M—<0.01%no changeJun 30, 2026
🇺🇸 State Street SPDR Portfolio Emerging Markets ETFSSGA Funds Management, Inc.38,157$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Total International Index FundFidelity Management & Research Company LLC37,302$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Dimensional World ex. U.S. Core Equity 2 ETFDimensional Fund Advisors LP29,904$0 M—<0.01%+36%Jul 31, 2026
🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP20,502$0 M—<0.01%−5.9%Jul 31, 2026
🇺🇸 Emerging Markets Social Core Equity PortfolioDimensional Fund Advisors LP19,489$0 M—<0.01%−27%Jul 31, 2026
🇺🇸 Dimensional Emerging Core Equity Market ETFDimensional Fund Advisors LP17,475$0 M—<0.01%−30%Jul 31, 2026
🇺🇸 Strategic Advisers Emerging Markets FundStrategic Advisers LLC15,281$0 M—<0.01%no changeMay 31, 2026
🇺🇸 iShares MSCI Emerging Markets Small-Cap ETFBlackRock Fund Advisors13,764$0 M—0.03%no changeMay 31, 2026
🇺🇸 Emerging Markets Sustainability Core 1 PortfolioDimensional Fund Advisors LP9,666$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Esg International Stock ETFThe Vanguard Group, Inc.9,875$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Dimensional Emerging Markets Value ETFDimensional Fund Advisors LP8,679$0 M—<0.01%no changeJul 31, 2026
🇺🇸 State Street SPDR S&P Emerging Asia Pacific ETFSSGA Funds Management, Inc.8,127$0 M—0.02%+7.7%Jun 30, 2026
🇺🇸 Emerging Markets Targeted Value PortfolioDimensional Fund Advisors LP8,442$0 M—0.02%no changeJul 31, 2026
🇺🇸 State Street Global All Cap Equity ex-U.S. Index PortfolioSSGA Funds Management, Inc.7,522$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Avantis Emerging Markets Equity FundAmerican Century ETF Trust8,197$0 M—<0.01%no changeMay 31, 2026
🇺🇸 World ex U.S. Targeted Value PortfolioDimensional Fund Advisors LP7,407$0 M—<0.01%no changeJul 31, 2026
🇺🇸 SA Emerging Markets Value FundFocus Advisor Solutions, LLC4,429$0 M—0.02%no changeJun 30, 2026
🇺🇸 Emerging Markets ex China Core Equity PortfolioDimensional Fund Advisors LP4,604$0 M—<0.01%−56%Jul 31, 2026
🇺🇸 Dimensional Emerging Markets ex China Core Equity ETFDimensional Fund Advisors LP2,880$0 M—<0.01%−1.1%Jul 31, 2026
🇺🇸 Avantis Emerging Markets Small Cap Equity ETFAmerican Century ETF Trust3,096$0 M—0.02%no changeMay 31, 2026
🇺🇸 Dimensional World ex U.S. Sustainability Targeted Value PortfolioDimensional Fund Advisors LP2,525$0 M—<0.01%+124%Jul 31, 2026
🇺🇸 FlexShares Morningstar Emerging Markets Factor Tilt Index FundNorthern Trust Investments, Inc.2,000$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Dimensional Emerging Markets Sustainability Core 1 ETFDimensional Fund Advisors LP1,807$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Avantis Emerging Markets ex-China Equity ETFAmerican Century ETF Trust285$0 M—<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Oct 31, 2026. The 45 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Where Alembic Pharmaceuticals Limited operates: 1 country#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Present: offices, subsidiaries, branches or revenue (1 country)Nothing on fileDots mark countries too small to see. Hover, tap or tab to a country for its figures.

Only the headquarters country is on file for Alembic Pharmaceuticals Limited: no subsidiaries, branches, offices or country revenue elsewhere in the GLEIF register, its SEC filings or Wikidata.

Alembic Pharmaceuticals Limited: countries of operation
CountryPresenceRevenue there
🇮🇳 IndiaHeadquarters1 office—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file; map outlines from Natural Earth. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

FDA drug approvals: Alembic Pharmaceuticals Limited#

16 approved applications held; 3 approvals and 0 new uses in 2013.

Approvals held
16
New molecular entities
0
New uses approved
0
efficacy supplements
Generics
15
1 new drugs, 0 biologics
Alembic Pharmaceuticals Limited: latest FDA approvals
ApprovedDrugKind
2013-05-28Metoprolol TartrateMetoprolol Tartrate · ANDA202871Generic drug (ANDA)
2013-03-04DesvenlafaxineDesvenlafaxine · NDA204150New drug (NDA)
2013-02-25Donepezil HydrochlorideDonepezil Hydrochloride · ANDA201724Generic drug (ANDA)
2012-10-15IrbesartanIrbesartan · ANDA091236Generic drug (ANDA)
2012-06-12Rivastigmine TartrateRivastigmine Tartrate · ANDA091689Generic drug (ANDA)
2012-02-17Losartan Potassium And HydrochlorothiazideHydrochlorothiazide, Losartan Potassium · ANDA091617Generic drug (ANDA)
2011-12-06Clonidine HydrochlorideClonidine Hydrochloride · ANDA091368Generic drug (ANDA)
2011-11-21LeflunomideLeflunomide · ANDA091369Generic drug (ANDA)
2011-01-13LamotrigineLamotrigine · ANDA090607Generic drug (ANDA)
2010-12-14Venlafaxine HydrochlorideVenlafaxine Hydrochloride · ANDA078932Generic drug (ANDA)
2010-11-30HydrochlorothiazideHydrochlorothiazide · ANDA200645Generic drug (ANDA)
2010-10-06Losartan PotassiumLosartan Potassium · ANDA090428Generic drug (ANDA)
2009-05-22FamotidineFamotidine · ANDA078916Generic drug (ANDA)
2009-03-19Fluoxetine HydrochlorideFluoxetine Hydrochloride · ANDA090223Generic drug (ANDA)
2009-03-13MetronidazoleMetronidazole · ANDA079067Generic drug (ANDA)
2009-02-18MeprobamateMeprobamate · ANDA090122Generic drug (ANDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (ALEMBIC PHARMS LTD), so they follow acquisitions

Product recalls by Alembic Pharmaceuticals Limited#

9 recalls since 2015, 134,007 units in the notices that give a number. Drugs (FDA): 9.

Alembic Pharmaceuticals Limited: product recalls
DateWhat and whyUnitsNotice
Fesoterodine Fumarate, Extended-release Tablets, 8 mg, 30 Tablets, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panelav 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-176-30Failed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.DrugsClass III—D-0248-2026
Fesoterodine Fumarate, Extended-release Tablets, 4 mg, 30-count bottle, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panelav 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-175-30Failed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.DrugsClass III4,884D-0156-2026
Doxepin Hydrochloride Capsules, USP, 10 mg, 100 Capsules, Rx only, Manufactured by: Alembic Pharmaceuticals Limited, Panela v 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-637-31CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.DrugsClass II9,492D-0566-2025
Celecoxib Capsules, 200 mg, 500-count bottle, Rx only, Manufactured by: Alembic Pharmaceuticals Limited (Formulation Division), Panelav 389350, Gujarat, India, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, NDC 62332-142-71Presence of Foreign Tablets/Capsules; customer complaint found one Tadalafil 5mg tablet inside a sealed 500-count bottle of Celecoxib 200mg capsuleDrugsClass II2,946D-0459-2025
Bromfenac Ophthalmic Solution 0.09%, 1.7 mL bottle, Rx only, Sterile, Manufactured for: Alembic Pharmaceuticals, Inc., Bedminster, NJ 07921, USA, Manufactured by Alembic Pharmaceuticals Limitied, Gujarat, India, Made in India, NDC 62332-508-17Failed Impurities/Degradation SpecificationsDrugsClass II—D-0447-2025
Tobramycin Opthalmic Solution USP, 0.3%, 5mL bottle, Rx only, Manufactured for: Alembic Pharmaceuticals, Bedminster, NJ 07921, USA, NDC 62332-518-05Failed Impurities/Degradation SpecificationsDrugsClass III82,400D-1086-2023
Diclofenac Sodium Topical Solution USP, 2% w/w, 3.8 FL.OZ.(112 grams) bottles, Rx only, Manufactured for: Alembic Pharmaceuticals, Inc. Bedminster, NJ 07921, USA Manufactured by: Alembic Pharmaceuticals Limited (Derma Division) Karakhadi, Vadodara 391450, India. NDC 62332-487-12Defective Delivery SystemDrugsClass II2,844D-0941-2023
Telmisartan Tablets, USP 20 mg, 30-count bottles, Rx only, Manufactured by: Alembic Pharmaceuticals Limited (Formulation Division) Panelav 38935, Gujarat, India Manufactured for: Alembic Pharmaceuticals, Inc. 750 Route 202, Bridgewater, NJ 08807, NDC 62332-087-30Labeling: Label-mixupDrugsClass I12,288D-0326-2021
Aripiprazole Tablets, USP, 2 mg, 30 Tablets per bottle, Rx only, Manufactured by: Alembic Pharmaceuticals Limited (Formulation Division) Panelav 389350, Gujarat, India Manufactured for: Alembic Pharmaceuticals, Inc. 750 Route 202, Bridgewater, NJ 08807 USA, NDC 62332-097-30.Labeling: Label mix up: Bottles labeled as aripiprazole 2 mg, 30 count had aripiprazole 5 mg tablets, 100 count.DrugsClass II19,153D-1341-2020

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

Discuss Alembic Pharmaceuticals Limited#

1 automatic updates and 0 member comments. Sign in to comment and react.

  • Mutual funds: 45 funds hold $79 millionautomatic update · Oct 31, 2026

    45 mutual funds in 2 countries hold shares of Alembic Pharmaceuticals Limited worth $79 million (funds' newest reports, up to 31 October 2026). Since their previous reports 4 funds added shares and 11 sold; on balance they sold $1 million. Share splits are not counted as trading.

How Alembic Pharmaceuticals Limited compares in Pharmaceutical

  • Market cap$2.2 B · higher than 74% of 393
  • Revenue$664 M · higher than 54% of 324
  • Net margin10.2% · higher than 57% of 313
  • P/E ratio32.5× · lower than 36% of 172
  • Price / sales3.3× · lower than 39% of 219
  • Price / book3.4× · lower than 33% of 207

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Alembic Pharmaceuticals Limited🇮🇳$2.2 B32.5×10.2%—
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Nov 19, 2026
Annual results:
Mar-2022 ending year
Balance sheet:
Mar-2022 ending year
Employees:
As on March 2020
Profile updated:
Nov 20, 2026

Figures from Market data, value.today research, Wikipedia, GLEIF register.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Alembic Pharmaceuticals Limited? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Alembic Pharmaceuticals Limited's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Alembic Pharmaceuticals Limited? Suggest a correction